Combination therapy using Notch and Akt inhibitors is effective for suppressing invasion but not proliferation in glioma cells

Neuroscience Letters

Volumn 534, Issue 1, 2013, Pages 316-321

  Jin, Rihua ^a,b   Nakada, Mitsutoshi ^b   Teng, Lei ^b,c   Furuta, Takuya ^b   Sabit, Hemragul ^b   Hayashi, Yutaka ^b   Demuth, Tim ^d   Hirao, Atsushi ^b   Sato, Hiroshi ^b   Zhao, Gang ^a   Hamada, Jun ichiro ^b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b KANAZAWA UNIVERSITY   (Japan)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Akt; Glioma; Invasion; Molecular targeted therapy; Notch; Proliferation

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; MRK 003; NOTCH RECEPTOR; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INACTIVATION; GLIOMA CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIC S-OXIDES; DRUG INTERACTIONS; GLIOMA; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; THIADIAZOLES;

EID: 84873055757     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.12.008     Document Type: Article

References (18)

1. Androutsellis-Theotokis A., Leker R.R., Soldner F., Hoeppner D.J., Ravin R., Poser S.W., Rueger M.A., Bae S.K., Kittappa R., McKay R.D. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 2006, 442:823-826.
2. Chen J., Kesari S., Rooney C., Strack P.R., Shen H., Wu L., Griffin J.D. Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes & Cancer 2010, 1:822-835.
3. Chen K.F., Chen H.L., Tai W.T., Feng W.C., Hsu C.H., Chen P.J., Cheng A.L. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. The Journal of Pharmacology and Experimental Therapeutics 2011, 337:155-161.
4. Cheng Y., Ren X., Zhang Y., Patel R., Sharma A., Wu H., Robertson G.P., Yan L., Rubin E., Yang J.M. eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. Cancer Research 2011, 71:2654-2663.
5. Fouladi M., Stewart C.F., Olson J., Wagner L.M., Onar-Thomas A., Kocak M., Packer R.J., Goldman S., Gururangan S., Gajjar A., Demuth T., Kun L.E., Boyett J.M., Gilbertson R.J. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Journal of Clinical Oncology 2011, 29:3529-3534. (Epub ahead of print, 2011 Aug 8).
6. Iso T., Kedes L., Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. Journal of Cellular Physiology 2003, 194:237-255.
7. Kopan R., Ilagan M.X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137:216-233.
8. Krop I., Demuth T., Guthrie T., Wen P.Y., Mason W.P., Chinnaiyan P., Butowski N., Groves M.D., Kesari S., Freedman S.J., Blackman S., Watters J., Loboda A., Podtelezhnikov A., Lunceford J., Chen C., Giannotti M., Hing J., Beckman R., Lorusso P. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. Journal of Clinical Oncology 2012, 30:2307-2313. (Epub ahead of print, 2012 Apr 30).
9. Miele L., Golde T., Osborne B. Notch signaling in cancer. Current Molecular Medicine 2006, 6:905-918.
10. Nakada M., Kita D., Teng L., Pyko I.V., Watanabe T., Hayashi Y., Hamada J. Receptor tyrosine kinases: principles and functions in glioma invasion. Advances in Experimental Medicine and Biology 2013, 986:143-170.
11. Nakada M., Kita D., Watanabe T., Hayashi Y., Teng L., Pyko I.V., Hamada J.-I. Aberrant signaling pathways in glioma. Cancers 2011, 3:3242-3278.
12. Sun Y., Gao X., Liu J., Kong Q.Y., Wang X.W., Chen X.Y., Wang Q., Cheng Y.F., Qu X.X., Li H. Differential Notch1 and Notch2 expression and frequent activation of Notch signaling in gastric cancers. Archives of Pathology & Laboratory Medicine 2011, 135:451-458.
13. Wang Z., Banerjee S., Li Y., Rahman K.M., Zhang Y., Sarkar F.H. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Research 2006, 66:2778-2784.
14. Yap T.A., Yan L., Patnaik A., Fearen I., Olmos D., Papadopoulos K., Baird R.D., Delgado L., Taylor A., Lupinacci L., Riisnaes R., Pope L.L., Heaton S.P., Thomas G., Garrett M.D., Sullivan D.M., de Bono J.S., Tolcher A.W. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. Journal of Clinical Oncology 2011, 29:4688-4695.
15. Yoshida Y., Nakada M., Sugimoto N., Harada T., Hayashi Y., Kita D., Uchiyama N., Yachie A., Takuwa Y., Hamada J. Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. International Journal of Cancer 2010, 126:2341-2352.
16. Zhang X., Chen T., Zhang J., Mao Q., Li S., Xiong W., Qiu Y., Xie Q., Ge J. Notch1 promotes glioma cell migration and invasion by stimulating beta-catenin and NF-kappaB signaling via AKT activation. Cancer Science 2012, 103:181-190.
17. Zhao N., Guo Y., Zhang M., Lin L., Zheng Z. Akt-mTOR signaling is involved in Notch-1-mediated glioma cell survival and proliferation. Oncology Reports 2010, 23:1443-1447.
18. Zhou L., Wang D.S., Li Q.J., Sun W., Zhang Y., Dou K.F. Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor. Oncology Reports 2012, 28:874-882. (Epub ahead of print, 2012 Jun 20).